Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of BMN 165 (pegvaliase) in Japanese Adults With Phenylketonuria
jRCT2080224573Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegvaliase in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Started Feb 2019; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on jRCT2080224573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224573.